Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemiaDUMON, J. C; MAGRITTE, A; BODY, J. J et al.Bone and mineral. 1991, Vol 15, Num 3, pp 257-266, issn 0169-6009Article

Prevention of postmenopausal bone loss by tiludronateREGINSTER, J. Y; LECART, M. P; DEROISY, R et al.Lancet (British edition). 1989, Num 8678/8679, pp 1469-1471, issn 0140-6736Article

Multiple dose pharmacokinetics of tiludronate in healthy volunteersSCHWIETERT, H. R; PEETERS, P. A. M; DINGEMANSE, J et al.European journal of clinical pharmacology. 1996, Vol 51, Num 2, pp 175-181, issn 0031-6970Article

Sodium lauryl sulphate increases tiludronate paracellular transport using human epithelial Caco-2 monolayersBOULENC, X; BREUL, T; GAUTIER, J.-C et al.International journal of pharmaceutics. 1995, Vol 123, Num 1, pp 71-83, issn 0378-5173Article

Longitudinal effect of tiludronate on bone mineral density, resonant frequency, and strength in monkeysGEUSENS, P; NIJS, J; DEQUEKER, J et al.Journal of bone and mineral research (Print). 1992, Vol 7, Num 6, pp 599-609, issn 0884-0431Article

Oral tiludronate : pharmacological properties and potential usefulness in Paget's disease of bone on osteoporosisREGINSTER, J. Y. L.Bone (New York, NY). 1992, Vol 13, Num 5, pp 351-354, issn 8756-3282Conference Paper

Nouveaux inhibiteurs de la résorption osseuse = New inhibitors of the bone resorptionBEAUDREUIL, J; KUNTZ, D.L' Actualité rhumatologique. 1996, pp 207-220, issn 0065-1818Article

Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of boneROUX, C; GENNARI, C; FARRERONS, J et al.Arthritis and rheumatism. 1995, Vol 38, Num 6, pp 851-858, issn 0004-3591Article

The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H⁺-ATPaseDAVID, P; NGUYEN, H; BARBIER, A et al.Journal of bone and mineral research (Print). 1996, Vol 11, Num 10, pp 1498-1507, issn 0884-0431Conference Paper

Effects of tiludronate on bone loss in paraplegic patientsCHAPPARD, D; MINAIRE, P; GAUD, C et al.Journal of bone and mineral research (Print). 1995, Vol 10, Num 1, pp 112-118, issn 0884-0431Article

Paget's disease of bone treated with a five day course of oral tiludronateREGINSTER, J. Y; LECART, M. P; DEROISY, R et al.Annals of the rheumatic diseases. 1993, Vol 52, Num 1, pp 54-57, issn 0003-4967Article

TiludronateLa Revue Prescrire. 1996, Vol 16, Num 167, pp 744-748, issn 0247-7750Article

Effects of tiludronate on bone mass, structure, and turnover at the epiphyseal, primary, and secondary spongiosa in the proximal tibia of growing rats after sciatic neurectomyMURAKAMI, H; NAKAMURA, T; TSURUKAMI, H et al.Journal of bone and mineral research (Print). 1994, Vol 9, Num 9, pp 1355-1364, issn 0884-0431Article

Effects of the bisphosphonate tiludronate on bone resorption, calcium balance, and bone mineral densityAMMANN, P; RIZZOLI, R; CAVERZASIO, J et al.Journal of bone and mineral research (Print). 1993, Vol 8, Num 12, pp 1491-1498, issn 0884-0431Article